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Introduction
Community-acquired pneumonia (CAP) is a common infectious 
reason for hospitalization of adults in the United States (US), 
including those with Human Immunodeficiency Virus (HIV) 
[1-3]. Some articles have suggested that HIV patients are 
actually more likely to be hospitalized with CAP, regardless of 
their pneumonia severity index (PSI) score, than other adult 
populations secondary to their immunosuppressed status [4]. 
Current assessment of the incidence and outcomes of HIV 
patients hospitalized with CAP is important to guide ongoing 
prevention and management [5].
While there are studies detailing the incidence and outcomes for 
all adults with CAP we are not aware of a recent study detailing 
incidence and outcomes in adult HIV patients hospitalized with 
CAP.
The objectives of this study were (1) to define the current 
incidence and outcomes of adult HIV patients hospitalized with 
CAP in Louisville, Kentucky, and (2) to estimate the burden of 
CAP in the US HIV adult population.
Methods
Study Design
This was a secondary analysis of The University of Louisville 
Pneumonia Study; a prospective population-based cohort 
study of all hospitalized adults with CAP who were residents 
of Louisville, Kentucky, from 1 June 2014 to 31 May 2016 (IRB 
number 11.0613). All hospitalized adult patients in Louisville 
underwent screening for participation in the study during that 
time. Patients without a permanent or valid Louisville address 
based on US Census Bureau data, without a valid Social Security 
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number (SSN), or who were in the correctional system were not 
included. Data was collected on participants from the medical 
record including; age, sex, race, body mass index (BMI), HIV 
status, presence of malignancy, presence of renal disease, 
presence of heart disease, presence of chronic obstructive 
pulmonary disease (COPD), history of cerebrovascular event 
(CVA), smoking status, presence of diabetes, temperature, 
respiratory rate, blood pressure, heart rate, serum bicarbonate, 
blood urea nitrogen, serum glucose, serum hematocrit, serum 
sodium, admission location, presence of altered mental status 
(AMS), vasopressor requirements, ventilator requirements, and 
PSI score.
Study Design
A patient was defined as having CAP when the following 3 
criteria were met: 
1. Presence of a new pulmonary infiltrate on chest radiograph 
and/or chest computed tomography scan at the time of 
hospitalization, defined by a board certified radiologist’s 
reading
2. At least 1 of the following: 
a. New cough or increased cough or sputum production,
b. Fever >37.8°C (100.0°F) or hypothermia <35.6°C 
(96.0°F), 
c. Changes in leukocyte count (leukocytosis: >11,000 
cells/μL; left shift: >10% band forms/mL; or 
leukopenia: <4,000 cells/μL)
3. No alternative diagnosis at the time of hospital discharge 
that justified the presence of criteria 1 and 2.
A patient was determined to have HIV based on either prior 
diagnosis noted in past medical history on chart review or 
new diagnosis (performed at the discretion of the hospital 
physician) made via the fourth generation HIV screening test in 
combination with viral load and CD4 count.
A unique HIV patient hospitalized with CAP was counted as the 
first hospitalization during each study year. 
Study Measures
The annual CAP incidence rates in adult HIV patients per 
100,000 adults were estimated for unique patients. The 
estimated number of CAP cases in HIV patients in the United 
States was calculated by multiplying the Louisville incidence 
rate by the estimated 2014 US adult population obtained from 
the US Census Bureau.
Time to clinical stability was defined as the number of days from 
admission up until the patient reached clinical stability, which 
was defined as the presence of all four criteria:
1. Improvement of cough and dyspnea
2. Absence of fever (<37.8 °C) for at least 8 h
3. Normalization or greater than 10% improvement of white 
blood cell count
4. Adequate oral intake
Length of hospital stay was defined as the number of days from 
admission to discharge.
All-cause mortality for all hospitalized unique HIV patients 
with CAP was evaluated during hospitalization and at 30 days, 6 
months, and 1 year after hospitalization. To ensure appropriate 
1-year follow-up, mortality was evaluated for patients enrolled 
in the first year of the study. After discharge, mortality was 
evaluated by reviewing medical records and by matching 
patients’ SSNs with mortality data obtained from the Kentucky 
Department for Public Health Office of Vital Statistics. Mortality 
data from Louisville were extrapolated to the US population 
hospitalized with CAP.
Results
The patient characteristics for HIV patients hospitalized with 
CAP during this study are detailed in Table 1.
Table 1 Patient characteristics.
A total of 110 unique patients living with HIV were hospitalized 
with CAP during our two-year study. In 2016 there were 2,821 
adults living with HIV in Louisville Kentucky [6]. Therefore, the 
annual incidence of adults living with HIV hospitalized with CAP 
is estimated to be 1,950 per 100,000. Of the estimated 1.1 million 
adults living with HIV in the US currently we predict that 21,450 
will be hospitalized with CAP annually [7]. The median time to 
clinical stability in adult patients living with HIV hospitalized 
with CAP was 2 (IQR: [1, 3]) days. The median length of stay 
for adult patients living with HIV hospitalized with CAP was 4 
(IQR: [3, 7]) days. Mortality occurred as follows; in-hospital: 
1.8%, 30-day 6.8%, 6-month 15.5%, and 1 year 20.2%.
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Demographics   
Age, Median(IQR) 51 (16) 
Male Sex, n(%) 72 (65.5) 
Black or African American Race, n(%) 58 (52.7) 
Medical and Social History   
Obese, n(%) 19 (17.3) 
HIV disease, n(%) 110 (100) 
Neoplastic disease (active or within the last year), n(%) 14 (12.7) 
Renal disease, n(%) 27 (24.5) 
Chronic renal failure, n(%) 10 (9.1) 
Congestive heart failure, n(%) 18 (16.4) 
Chronic Obstructive Pulmonary Disease (COPD), n(%) 41 (37.3) 
Stroke, n(%) 5 (4.5) 
Current Smoker, n(%) 65 (59.1) 
Diabetes mellitus, n(%) 15 (13.6) 
Physical Exam Findings   
Temperature (Degrees Celsius), Median(IQR) 37.6 (1.6) 
Respiratory rate (Breaths/Minute), Median(IQR) 22 (8) 
Systolic blood pressure (mmHg), Median(IQR) 109 (32.8) 
Diastolic blood pressure (mmHg), Median(IQR) 60 (19.8) 
Heart rate (Beats/Minute), Median(IQR) 112 (24.2) 
Laboratory Findings   
Serum bicarbonate (mEq/L), Median(IQR) 25 (6) 
Blood Urea Nitrogen (BUN) (mg/dL), Median(IQR) 15 (11.5) 
Serum glucose (mg/dl), Median(IQR) 121 (43.8) 
Hematocrit (%), Median(IQR) 34.3 (8.9) 
Serum sodium (mEq/L), Median(IQR) 136 (7) 
Severity of Disease   
ICU Admission, n(%) 15 (13.6) 
Altered mental status on admission, n(%) 8 (7.3) 
Vasopressors on admission, n(%) 0 (0) 
Ventilatory support on admission?, n(%) 6 (5.5) 
Pneumonia Severity Index, Median(IQR) 75.5 (66.8) 
PSI Risk Class IV or V, n(%) 41 (37.3) 
 
Discussion
We estimated the annual incidence of adults living with HIV 
hospitalized with CAP to be 1,950 per 100,000 suggesting that 
21,450 adults living with HIV will be hospitalized with CAP 
yearly across the US. A review of the literature did not reveal 
a recent study on incidence of adult patients living with HIV 
hospitalized with CAP in the US for comparison. However, 
looking at our data it is notable that there does seem to be a 
lower threshold for hospitalizing adult patients living with HIV 
for CAP than for the general adult population. Compared to a 
recent publication detailing the incidence, epidemiology, and 
mortality of all adults with CAP in the US, Ramirez et al, adults 
living with HIV presenting with CAP were admitted at younger 
ages and with lower PSI scores. That study indicated that the 
average age of admission for all adults with CAP was 68 whereas 
the average age of admission for adult patients living with HIV 
presenting with CAP was 51. That study also indicated that the 
average PSI score for adults admitted with CAP was 101 whereas 
the average PSI score for adults living with HIV admitted with 
CAP was 75.
Interestingly, when compared to the same study, the annual 
incidence of adults living with HIV hospitalized with CAP of 
1,950 per 100,000 is very similar to that in the elderly. While 
the overall incidence of hospitalizations in all adult patients 
with CAP was 649 per 100,000 the incidence in the elderly (age 
greater than or equal to 65) increased drastically to 2093 per 
100,000. This suggests that like the elderly, patients living with 
HIV are 3 times more likely to be hospitalized with CAP than the 
general adult population. 
However, when comparing mortality from the same study, the 
mortality was lower for adults living with HIV hospitalized 
with CAP than all adults hospitalized with CAP at 1.8% vs 6.5% 
during hospitalization, 6.8% vs 13% at 30 days, 15.5% vs 23.4% 
at 6 months, and 20.2% vs 30.6% at 1 year [6]. This may reflect 
the lower threshold for hospital admission in adults living with 
HIV for CAP regardless of their severity of illness. A review of 
the literature on mortality in adult patients living with HIV 
with CAP revealed that our value for 30-day mortality of 6.8% 
was similar to the 30-day mortality described in a recent study 
by Cilloniz et al. that reported a 7% 30-day mortality in adults 
living with HIV hospitalized with CAP in Spain [8].  
Our study has several limitations, the primary one being the 
lack of a gold diagnostic standard test for pneumonia.  In our 
study, patients hospitalized with signs and symptoms of a 
respiratory infection, with a new pulmonary infiltrate, and 
no clear alternative diagnosis were classified as having CAP. 
Immunosuppressed patients may not meet the aforementioned 
criteria despite the presence of CAP, and the sensitivity and 
specificity of our definition is unknown due to the lack of a 
gold standard. Secondly, if a patient from Louisville living 
with HIV was hospitalized with CAP outside of Louisville they 
would not have been included in this study. This means that 
we have potentially underestimated the incidence of adult 
patients living with HIV hospitalized with CAP. Also, because 
we used 2010 US Census Bureau information to calculate 
incidence we excluded patients not included in the US Census 
Bureau data; those without a valid address, SSN, or who were 
incarcerated. While this would not affect our incidence, it could 
potentially introduce selection bias. Lastly, our study does not 
detail the CD4 counts, viral loads, anti-retroviral therapy, or 
pneumococcal and influenza vaccination status of the patients 
living with HIV hospitalized for CAP. Therefore, it is difficult to 
extrapolate the overall immune status of the patients living with 
HIV included in the study. 
Overall, we do feel that we were able to accurately capture the 
number of adult patients living with HIV in Louisville that were 
admitted with CAP during the study as all nine area hospitals 
were under constant surveillance for two years. We also believe 
that the incidence of HIV in Louisville, a medium sized city, is 
a good population to reflect overall HIV incidence and activity 
across the US opposed to larger or smaller cities which may over 
or under represent the presence of HIV. 
In conclusion, the estimated annual incidence of adult patients 
living with HIV and hospitalized with CAP was found to be 1,950 
per 100,000 suggesting that 21,450 adults living with HIV will 
be admitted with CAP yearly across the US. This is a similar 
incidence to that recently predicted for the elderly. Mortality 
occurred as follows; in-hospital: 1.8%, 30-day 6.8%, 6-month 
15.5%, and 1 year 20.2%. Our 30-day mortality rate for adult 
patients living with HIV hospitalized for CAP was similar to 
other figures in the literature. Further research is needed to 
determine the overall immune status of and risk factors for 
adults living with HIV hospitalized with CAP. The incidence 
of pneumococcal and influenza vaccination in patients living 
with HIV admitted with CAP in tandem with microbiological 
data regarding causative pathogens needs further investigation 
as well. Pneumococcal and influenza vaccination may be over 
represented in this patient population compared to all adults. 
This may both explain milder disease in HIV patients and direct 
future vaccine development.
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